Julia Rotow

3.9k total citations · 1 hit paper
47 papers, 1.1k citations indexed

About

Julia Rotow is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Julia Rotow has authored 47 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Pulmonary and Respiratory Medicine, 33 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Julia Rotow's work include Lung Cancer Treatments and Mutations (39 papers), Colorectal Cancer Treatments and Studies (15 papers) and Lung Cancer Research Studies (15 papers). Julia Rotow is often cited by papers focused on Lung Cancer Treatments and Mutations (39 papers), Colorectal Cancer Treatments and Studies (15 papers) and Lung Cancer Research Studies (15 papers). Julia Rotow collaborates with scholars based in United States, Japan and South Korea. Julia Rotow's co-authors include Trever G. Bivona, Geoffrey R. Oxnard, Pasi A. Jänne, Collin M. Blakely, Jonathan W. Riess, Zofia Piotrowska, Caroline E. McCoach, Justin F. Gainor, Mark M. Awad and Benjamin Izar and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Nature reviews. Cancer.

In The Last Decade

Julia Rotow

41 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Understanding and targeting resistance mechanisms in NSCLC

2017 684 citations Julia Rotow, Trever G. Bivona Nature reviews. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julia Rotow United States	14	654	609	582	316	85	47	1.1k
Patrick Urban Switzerland	13	665 1.0×	746 1.2×	560 1.0×	255 0.8×	100 1.2×	31	1.2k
Jordi Bertrán-Alamillo Spain	14	514 0.8×	472 0.8×	437 0.8×	299 0.9×	82 1.0×	33	838
Ana Drozdowskyj Spain	13	505 0.8×	632 1.0×	490 0.8×	317 1.0×	92 1.1×	31	1.0k
Masaki Shimoji Japan	15	775 1.2×	676 1.1×	434 0.7×	204 0.6×	93 1.1×	38	1.1k
Douglas E. Linn United States	11	953 1.5×	334 0.5×	847 1.5×	379 1.2×	111 1.3×	17	1.5k
Kiyoko Kuwata Japan	14	599 0.9×	555 0.9×	561 1.0×	141 0.4×	140 1.6×	19	1.0k
Erina Hatashita Japan	15	492 0.8×	579 1.0×	588 1.0×	130 0.4×	126 1.5×	17	1.0k
Filippo Petti United States	7	437 0.7×	789 1.3×	829 1.4×	298 0.9×	119 1.4×	8	1.4k
Gareth Hughes United Kingdom	13	321 0.5×	627 1.0×	694 1.2×	266 0.8×	80 0.9×	22	1.3k
Kinisha Gala United States	7	412 0.6×	532 0.9×	524 0.9×	409 1.3×	75 0.9×	10	1.1k

Countries citing papers authored by Julia Rotow

Since Specialization

Citations

This map shows the geographic impact of Julia Rotow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia Rotow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia Rotow more than expected).

Fields of papers citing papers by Julia Rotow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julia Rotow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia Rotow. The network helps show where Julia Rotow may publish in the future.

Co-authorship network of co-authors of Julia Rotow

This figure shows the co-authorship network connecting the top 25 collaborators of Julia Rotow. A scholar is included among the top collaborators of Julia Rotow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julia Rotow. Julia Rotow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Florez, Narjust, Nicole R. LeBoeuf, Julia Rotow, et al.. (2025). Mitigation and management of adverse events associated with amivantamab therapy. The Oncologist. 30(7).

Mak, Raymond H., Michael Lanuti, Alona Muzikansky, et al.. (2024). The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC. The Oncologist. 29(7). 609–618. 8 indexed citations

Lim, Sun Min, Stefanie S. Schalm, Sewon Park, et al.. (2024). BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer. Therapeutic Advances in Medical Oncology. 16. 7 indexed citations

Sharp, John, Daniel Jones, Julia Rotow, et al.. (2024). Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non–Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network. 22(3).

Leighl, Natasha B., Calvin S.H. Ng, David Planchard, et al.. (2024). Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report. Frontiers in Oncology. 13. 1330468–1330468.

Brea, Elliott J. & Julia Rotow. (2023). Targeted Therapy for Non–Small Cell Lung Cancer. Hematology/Oncology Clinics of North America. 37(3). 575–594.

Rotow, Julia, Saiama N. Waqar, K. Papadopoulos, et al.. (2023). 1318MO First-in-human study of ABBV-637, an EGFR-targeting BCL-XL–inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed/refractory, EGFR-mutated non-small cell lung cancer (NSCLC). Annals of Oncology. 34. S759–S759. 4 indexed citations

Tzeng, Alice, Kelly Fitzgerald, Jaclyn LoPiccolo, et al.. (2023). Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study. JTO Clinical and Research Reports. 4(10). 100559–100559. 6 indexed citations

Rotow, Julia, Jyoti D. Patel, Helena A. Yu, et al.. (2023). Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR -Mutant and RET Fusion-Positive Lung Cancers. Clinical Cancer Research. 29(16). 2979–2987. 26 indexed citations

10.

Ricciuti, Biagio, Melissa Gildenberg, Ankit Singh, et al.. (2023). Amplification of wild-type RET and clinical response to selpercatinib for non–small-cell lung cancer (NSCLC).. Journal of Clinical Oncology. 41(16_suppl). 9123–9123. 1 indexed citations

11.

Lynch, Donna‐Marie, et al.. (2023). Anaphylaxis and systemic mastocytosis controlled with KIT inhibitors in a patient with metastatic lung adenocarcinoma. Annals of Allergy Asthma & Immunology. 131(5). 668–670. 1 indexed citations

12.

Rotow, Julia, Jessica Lee, Russell W. Madison, et al.. (2023). Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib. Journal of Thoracic Oncology. 19(2). 227–239. 23 indexed citations

13.

Rotow, Julia, Kiyotaka Yoh, Ruth Perets, et al.. (2022). 1185TiP First-in-human phase I study of ABBV-637 as monotherapy and in combination in patients with relapsed and refractory solid tumors. Annals of Oncology. 33. S1090–S1090. 2 indexed citations

14.

Gabrail, N., Dipesh Uprety, Julia Rotow, et al.. (2022). 22P EMB-01: An EGFR-cMET bispecific antibody, in advanced/metastatic solid tumors phase I results. Annals of Oncology. 33. S39–S40. 12 indexed citations

15.

Rotow, Julia, Anatoly Urisman, Caroline E. McCoach, et al.. (2019). P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S578–S578. 6 indexed citations

16.

Neel, Dana S., Victor Olivas, Manasi K. Mayekar, et al.. (2018). Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins. Cancer Research. 79(3). 546–556. 63 indexed citations

17.

Rotow, Julia, Gavitt A. Woodard, Anatoly Urisman, et al.. (2018). Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation. Clinical Lung Cancer. 20(2). e137–e141. 9 indexed citations

18.

Rotow, Julia & Trever G. Bivona. (2017). Understanding and targeting resistance mechanisms in NSCLC. Nature reviews. Cancer. 17(11). 637–658. 684 indexed citations breakdown →

19.

Izar, Benjamin, Julia Rotow, Justin F. Gainor, Jeffrey W. Clark, & Bruce A. Chabner. (2013). Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer. Pharmacological Reviews. 65(4). 1351–1395. 25 indexed citations

20.

Ginther, Charles, et al.. (2010). RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis. Lung Cancer. 70(3). 253–262. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact